Rifaximin was first approved in Italy back in 1987, so they had to file for approval years before that. By all logic, the patent should have expired no later than 2007. But patent/IP laws in the U.S. are insane. Somehow, Salix Pharmaceuticals is still holding onto a U.S. patent for rifaximin (Xifaxan) until 2029.